Abstract
β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is a biological and positional candidate gene for Alzheimer’s disease (AD). BACE1 is a protease that catalyses APP cleavage at the β-secretase site. We evaluated all common and putatively functional polymorphisms in the genomic region encompassing BACE1 for an association with AD, and for functional effects on platelet β-secretase activity. Tag SNPs (n = 10) derived from phase II of the International HapMap Project, and a nonsynonymous variant, were successfully genotyped in 901 Caucasian individuals from Northern Ireland using Sequenom iPLEX and TaqMan technologies. APOE genotyping was performed by PCR-RFLP. Platelet membrane β-secretase activity was assayed in a subset of individuals (n = 311). Hardy–Weinberg equilibrium was observed for all variants. Evidence for an association with AD was observed with multi-marker haplotype analyses (P = 0.01), and with rs676134 when stratified for APOE genotype (P = 0.02), however adjusting for multiple testing negated the evidence for association of this variant with AD. χ2 analysis of genotype and allele frequencies in cases versus controls for individual SNPs revealed no evidence for association (5% level). No genetic factors were observed that significantly influenced platelet membrane β-secretase activity. We have selected an appropriate subset of variants suitable for comprehensive genetic investigation of the BACE1 gene. Our results suggest that common BACE1 polymorphisms and putatively functional variants have no significant influence on genetic susceptibility to AD, or platelet β-secretase activity, in this Caucasian Northern Irish population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263–265. doi:10.1093/bioinformatics/bth457.
Blacker, D., Bertram, L., Saunders, A. J., Moscarillo, T. J., Albert, M. S., Wiener, H., et al. (2003). Results of a high-resolution genome screen of 437 Alzheimer’s disease families. Human Molecular Genetics, 12, 23–32. doi:10.1093/hmg/ddg007.
Cai, L., Tang, G., Chen, L., Zhang, B., Jiang, S., & Ren, D. (2005). Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer’s disease patients. Neuroreport, 16, 1023–1026. doi:10.1097/00001756-200506210-00028.
Carson, R., Craig, D., McGuinness, B., Johnston, J. A., O’Neill, F. A., Passmore, A. P., et al. (2008). Alpha 7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer’s disease. Journal of Medical Genetics, 45, 244–248. doi:10.1136/jmg.2007.052704.
Clarimon, J., Bertranpetit, J., Calafell, F., Boada, M., Tarraga, L., & Comas, D. (2003). Association study between Alzheimer’s disease and genes involved in Abeta biosynthesis, aggregation and degradation: Suggestive results with BACE1. Journal of Neurology, 250, 956–961. doi:10.1007/s00415-003-1127-8.
Cruts, M., Dermaut, B., Rademakers, R., Roks, G., Van den Broeck, M., Munteanu, G., et al. (2001). Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer’s disease. Neuroscience Letters, 313, 105–107. doi:10.1016/S0304-3940(01)02234-0.
de Bakker, P. I., Yelensky, R., Pe’er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. (2005). Efficiency and power in genetic association studies. Nature Genetics, 37, 1217–1223. doi:10.1038/ng1669.
Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., et al. (2002). The structure of haplotype blocks in the human genome. Science, 296, 2225–2229. doi:10.1126/science.1069424.
Gold, G., Blouin, J. L., Herrmann, F. R., Michon, A., Mulligan, R., Duriaux Sail, G., et al. (2003). Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 119, 44–47. doi:10.1002/ajmg.b.10010.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., et al. (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 359, 322–325. doi:10.1038/359322a0.
Hubbard, T. J., Aken, B. L., Beal, K., Ballester, B., Caccamo, M., Chen, Y., et al. (2007). Ensembl 2007. Nucleic Acids Research, 35, D610–D617. doi:10.1093/nar/gkl996.
Johnston, J. A., Cowburn, R. F., Norgren, S., Wiehager, B., Venizelos, N., Winblad, B., et al. (1994). Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell-lines from family members with the Swedish Alzheimers disease APP670/671 mutation. FEBS Letters, 354, 274–278. doi:10.1016/0014-5793(94)01137-0.
Johnston, J. A., Liu, W. W., Coulson, D. T., Todd, S., Murphy, S., Brennan, S., et al. (2008). Platelet beta-secretase activity is increased in Alzheimer’s disease. Neurobiology of Aging, 29, 661–668. doi:10.1016/j.neurobiolaging.2006.11.003.
Johnston, J. A., Liu, W. W., Todd, S. A., Coulson, D. T., Murphy, S., Irvine, G. B., et al. (2005). Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer’s disease. Biochemical Society Transactions, 33, 1096–1100. doi:10.1042/BST20051096.
Kan, R., Wang, B., Zhang, C., Jin, F., Yang, Z., Ji, S., et al. (2005). Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer’s disease in Chinese. Journal of Molecular Neuroscience, 25, 127–131. doi:10.1385/JMN:25:2:127.
Kirschling, C. M., Kolsch, H., Frahnert, C., Rao, M. L., Maier, W., & Heun, R. (2003). Polymorphism in the BACE gene influences the risk for Alzheimer’s disease. Neuroreport, 14, 1243–1246. doi:10.1097/00001756-200307010-00011.
Liu, H. C., Leu, S. J., Chang, J. G., Sung, S. M., Hsu, W. C., Lee, L. S., et al. (2003). The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer’s disease. Brain Research, 961, 88–91. doi:10.1016/S0006-8993(02)03849-0.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.
Murphy, T., Yip, A., Brayne, C., Easton, D., Evans, J. G., Xuereb, J., et al. (2001). The BACE gene: Genomic structure and candidate gene study in late-onset Alzheimer’s disease. Neuroreport, 12, 631–634. doi:10.1097/00001756-200103050-00040.
Nicolaou, M., Song, Y. Q., Sato, C. A., Orlacchio, A., Kawarai, T., Medeiros, H., et al. (2001). Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer’s disease. Neurogenetics, 3, 203–206.
Nowotny, P., Kwon, J. M., Chakraverty, S., Nowotny, V., Morris, J. C., & Goate, A. M. (2001). Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport, 12, 1799–1802. doi:10.1097/00001756-200107030-00008.
Sambamurti, K., Kinsey, R., Maloney, B., Ge, Y. W., & Lahiri, D. K. (2004). Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB Journal, 18, 1034–1036.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine, 2, 864–870. doi:10.1038/nm0896-864.
Shi, J., Zhang, S., Tang, M., Liu, X., Li, T., Wang, Y., et al. (2004). The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer’s disease in Chinese Hans. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 124, 54–57. doi:10.1002/ajmg.b.20087.
Stockley, J. H., Ravid, R., & O’Neill, C. (2006). Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer’s disease brain. FEBS Letters, 580, 6550–6560. doi:10.1016/j.febslet.2006.10.076.
Tanzi, R. E., & Bertram, L. (2005). Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell, 120, 545–555. doi:10.1016/j.cell.2005.02.008.
Vassar, R. (2004). BACE1: The beta-secretase enzyme in Alzheimer’s disease. Journal of Molecular Neuroscience, 23, 105–114. doi:10.1385/JMN:23:1-2:105.
Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O’Connor, T., et al. (2007). Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer’s disease pathogenesis. Journal of Neuroscience, 27, 3639–3649. doi:10.1523/JNEUROSCI.4396-06.2007.
Acknowledgements
We would like to thank the Research & Development Office, Health and Personal Social Services, Northern Ireland; the Alzheimer’s Research Trust; and the Stewart Endowment for their generous financial support. We thank the American Federation for Aging Research for the award of a Beeson Fellowship to B.McG.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Todd, S., McKnight, A.J., Liu, W.W. et al. BACE1 Polymorphisms Do Not Influence Platelet Membrane β-secretase Activity or Genetic Susceptibility for Alzheimer’s Disease in the Northern Irish Population. Neuromol Med 10, 368–376 (2008). https://doi.org/10.1007/s12017-008-8045-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-008-8045-y